StockNews.com Begins Coverage on Cara Therapeutics (NASDAQ:CARA)

StockNews.com began coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a report released on Wednesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Price Performance

NASDAQ:CARA opened at $0.32 on Wednesday. The firm has a market capitalization of $17.78 million, a price-to-earnings ratio of -0.16 and a beta of 0.68. Cara Therapeutics has a 1 year low of $0.24 and a 1 year high of $1.31. The business has a 50 day simple moving average of $0.29 and a 200-day simple moving average of $0.40.

Cara Therapeutics (NASDAQ:CARA) last posted its quarterly earnings data on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.10). The company had revenue of $0.99 million during the quarter, compared to the consensus estimate of $1.26 million. Cara Therapeutics had a negative net margin of 1,010.20% and a negative return on equity of 241.31%. As a group, analysts expect that Cara Therapeutics will post -1.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cara Therapeutics

An institutional investor recently raised its position in Cara Therapeutics stock. Disciplined Growth Investors Inc. MN lifted its holdings in Cara Therapeutics, Inc. (NASDAQ:CARA) by 6.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,935,718 shares of the biopharmaceutical company’s stock after buying an additional 120,660 shares during the quarter. Disciplined Growth Investors Inc. MN owned approximately 3.54% of Cara Therapeutics worth $499,000 at the end of the most recent quarter. Institutional investors and hedge funds own 44.66% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.